304
Participants
Start Date
January 6, 2020
Primary Completion Date
October 1, 2024
Study Completion Date
October 1, 2024
Tavapadon
Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.
Placebo
Participants will receive placebo matching to tavapadon QD orally for 27 weeks.
Budapest, Budapest
Macquarie Park, New South Wales, Sydney
Tatabanya, Tatabánya
Pecs, Pécs
Torino, Torino
Ratchathewi, Bangkok, Ratchathewi
Belgrade, Belgrade
Khlong Luang, Pathum Thani, Khlong Luang
Berlin, Berlin
Albany, New York, Albany
Syracuse, New York, Syracuse
Marseille, France, Marseille
Rozzano Milano, Rozzano
Milano, Milan
Vinnitsa, Vinnitsa
Richmond, Virginia, Richmond
Richmond, Virginia, Richmond
Móstoles, Madrid, Madrid
Toulouse Cedex 9, Toulouse
Maitland, Florida, Maitland
Winter Park, Florida, Winter Park
Boca Raton, Florida, Boca Raton
Nai Muang, Ubon Ratchathani, Nai Muang
Ocala, Florida, Ocala
Memphis, Tennessee, Memphis
Nantes CEDEX 1, Nantes
Cleveland, Ohio, Cleveland
Bochum, Bochum
Cincinnati, Ohio, Cincinnati
Haeundae-gu, Busan, Busan
Houston, Texas, Houston
Cypress, Texas, Cypress
Round Rock, Texas, Round Rock
Lviv, Lviv
Lubbock, Texas, Lubbock
Muenchen, München
Fresno, California, Fresno
Kirkland, Washington, Kirkland
Zhongzheng, Taipei, Zhongzheng
Zhongzheng, Taipei, Zhongzheng
Boston Neuro Research Center, North Dartmouth
Gera, Gera
Cassino, Cassino
Rome, Rome
Cracow, Krakow
Siemianowice Slaskie, Siemianowice Śląskie
Centrum Medyczne NEUROMED, Bydgoszcz
Katowice, Katowice
Centrum Medyczne Hope Clinic Sebastian Szklener, Lublin
Dongdaemun-gu, Seoul, Seoul
Songpa-gu, Seoul, Seoul
Barcelona, Barcelona
Kiev, Kiev
Lead Sponsor
AbbVie
INDUSTRY